.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
McKinsey
Merck
Medtronic
QuintilesIMS
Cipla
Mallinckrodt
US Department of Justice
Moodys
Healthtrust

Generated: December 18, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021171

« Back to Dashboard

NDA 021171 describes DEMEROL, which is a drug marketed by Hospira and Us Pharm Holdings and is included in two NDAs. It is available from five suppliers. Additional details are available on the DEMEROL profile page.

The generic ingredient in DEMEROL is meperidine hydrochloride. There are six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the meperidine hydrochloride profile page.

Summary for 021171

Tradename:1
Applicant:1
Ingredient:1
Patents:0
Therapeutic Class:Analgesics
Formulation / Manufacturing:see details

Pharmacology for NDA: 021171

Mechanism of ActionFull Opioid Agonists

Medical Subject Heading (MeSH) Categories for 021171

Suppliers and Packaging for NDA: 021171

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
DEMEROL meperidine hydrochloride INJECTABLE;INJECTION 021171 NDA Hospira, Inc. 0409-1176 0409-1176-30 10 CARTRIDGE in 1 BOX (0409-1176-30) > 1 mL in 1 CARTRIDGE (0409-1176-03)
DEMEROL meperidine hydrochloride INJECTABLE;INJECTION 021171 NDA Hospira, Inc. 0409-1178 0409-1178-30 10 CARTRIDGE in 1 BOX (0409-1178-30) > 1 mL in 1 CARTRIDGE (0409-1178-03)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength25MG/ML
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength50MG/ML
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:INJECTABLE;INJECTIONStrength75MG/ML
Approval Date:Approved Prior to Jan 1, 1982TE:APRLD:Yes


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKinsey
Johnson and Johnson
Express Scripts
Fuji
US Department of Justice
Farmers Insurance
Federal Trade Commission
Argus Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot